Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. Necchi A, et al. Among authors: fare e. Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26. Invest New Drugs. 2014. PMID: 24566706 Clinical Trial.
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Necchi A, et al. Among authors: fare e. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14. Br J Cancer. 2014. PMID: 24231947 Free PMC article. Clinical Trial.
Erdafitinib for the treatment of urothelial cancer.
Marandino L, Raggi D, Giannatempo P, Farè E, Necchi A. Marandino L, et al. Among authors: fare e. Expert Rev Anticancer Ther. 2019 Oct;19(10):835-846. doi: 10.1080/14737140.2019.1671190. Epub 2019 Oct 4. Expert Rev Anticancer Ther. 2019. PMID: 31544541 Review.
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes.
Necchi A, Nicolai N, Mariani L, Raggi D, Farè E, Giannatempo P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Milani A, Piva L, Pizzocaro G, Gianni AM, Salvioni R. Necchi A, et al. Among authors: fare e. Ann Oncol. 2013 Nov;24(11):2887-92. doi: 10.1093/annonc/mdt271. Epub 2013 Jul 16. Ann Oncol. 2013. PMID: 23860612 Free article.
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes.
Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, Raggi D, Piva L, Catanzaro M, Biasoni D, Torelli T, Stagni S, Avuzzi B, Maffezzini M, Landoni G, De Braud F, Gianni AM, Sonpavde G, Salvioni R, Necchi A. Giannatempo P, et al. Among authors: fare e. Ann Oncol. 2015 Apr;26(4):657-668. doi: 10.1093/annonc/mdu447. Epub 2014 Sep 11. Ann Oncol. 2015. PMID: 25214543 Free article. Review.
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study.
Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, Raggi D, Farè E, Magni M, Piva L, Matteucci P, Catanzaro M, Biasoni D, Torelli T, Stagni S, Bengala C, Barone C, Schiavetto I, Siena S, Carlo-Stella C, Pizzocaro G, Salvioni R, Gianni AM. Necchi A, et al. Among authors: fare e. Ann Oncol. 2015 Jan;26(1):167-172. doi: 10.1093/annonc/mdu485. Epub 2014 Oct 24. Ann Oncol. 2015. PMID: 25344361 Free article. Clinical Trial.
Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.
Giannatempo P, Raggi D, Marandino L, Bandini M, Farè E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, Briganti A, Montorsi F, Madison R, Necchi A. Giannatempo P, et al. Among authors: fare e. Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23. Ann Oncol. 2020. PMID: 32979512 Free article. Clinical Trial.
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment.
Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Farè E, Catanzaro M, Biasoni D, Torelli T, Stagni S, Piva L, Mariani L, Salvioni R, Colecchia M, Gianni AM, Necchi A. Giannatempo P, et al. Among authors: fare e. J Urol. 2013 Nov;190(5):1919-24. doi: 10.1016/j.juro.2013.04.057. Epub 2013 Apr 25. J Urol. 2013. PMID: 23624209
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, Farè E, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Milani A, Gianni AM, Salvioni R. Necchi A, et al. Among authors: fare e. Clin Genitourin Cancer. 2014 Feb;12(1):63-69.e1. doi: 10.1016/j.clgc.2013.07.005. Epub 2013 Oct 23. Clin Genitourin Cancer. 2014. PMID: 24161525 Clinical Trial.
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, De Braud FG, Gianni AM, Salvioni R. Necchi A, et al. Among authors: fare e. Clin Genitourin Cancer. 2014 Jun;12(3):203-209.e1. doi: 10.1016/j.clgc.2013.11.022. Epub 2013 Nov 21. Clin Genitourin Cancer. 2014. PMID: 24394493
38 results